Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade

Author:

Søborg Andreas1ORCID,Reekie Joanne1,Sengeløv Henrik2,Da Cunha‐Bang Caspar2,Lund Thomas Kromann3,Ekenberg Christina1,Lodding Isabelle Paula1,Moestrup Kasper Sommerlund1,Lundgren Louise1,Lundgren Jens D.14,Wareham Neval Ete14

Affiliation:

1. Centre of Excellence for Health, Immunity, and Infections (CHIP), Copenhagen University Hospital/Rigshospitalet Copenhagen Denmark

2. Department of Hematology Copenhagen University Hospital/Rigshospitalet Copenhagen Denmark

3. Department of Cardiology, Section for Lung Transplantation Copenhagen University Hospital/Rigshospitalet Copenhagen Denmark

4. Department of Infectious Diseases Copenhagen University Hospital/Rigshospitalet Copenhagen Denmark

Abstract

AbstractObjectivesImproved survival after hematopoietic cell transplantation (HCT) and an increasingly comorbid transplant population may give rise to new trends in the causes of death.MethodsThis study includes all adult allogeneic HCT recipients transplanted at Rigshospitalet between January 1, 2010 and December 31, 2019. Underlying causes of death were determined using the Classification of Death Causes after Transplantation (CLASS) method.ResultsAmong 802 HCT recipients, 289 died during the study period. The main causes of death were relapse (N = 133, 46.0%), graft‐versus‐host disease (GvHD) (N = 64, 22.1%) and infections (N = 35, 12.1%). Multivariable analyses showed that with increasing transplant calendar year, a decreased risk of all‐cause mortality (HR 0.92, 95% CI 0.87–0.97) and death from GvHD (HR 0.87, 95% CI 0.78–0.97) was identified, but not for other specific causes.Standardized mortality ratios (SMRs) for all‐cause mortality decreased from 23.8 (95% CI 19.1–28.5) to 18.4 (95% CI 15.0–21.9) for patients transplanted in 2010–2014 versus 2015–2019, while SMR for patients who died from GvHD decreased from 8.19 (95% CI 5.43–10.94) to 3.65 (95% CI 2.13–5.18).ConclusionsAs risk of all‐cause mortality and death from GvHD decreases, death from relapse remains the greatest obstacle in further improvement of survival after HCT.

Funder

Danmarks Grundforskningsfond

Publisher

Wiley

Subject

Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3